南财智讯9月16日电，瑛泰医疗（01501.HK）发布须予披露交易公告，公司计划以5亿元人民币收购一家专注于外周血管介入医疗器械研发、生产和销售的目标公司控股权益。目标公司成立于2016年5月，已取得多项国家药监局颁发的注册证，并拥有超过300项专利。截至2024年10月31日，目标公司录得净亏损4887.97万元人民币。基于市场法估值，目标公司全部股东权益的估计价值为5亿元人民币。收购代价将由买方的内部资源支付，旨在平衡创始股东/ESOP平台与投资者股东的利益。董事会认为此次收购将丰富公司在外周血管介入领域的产品管线，并进一步完善产业布局。
（文章来源：南方财经网）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.